| Biotech Co.* | Pharma Co. (Country) | Type/Product Area | Disclosed Funding (M) | Terms/Details (Date) |
| | ||||
| 3-Dimensional Pharmaceu- | GlaxoSmith- | Exclusive licensing agreement that gives 3DP worldwide development, marketing and distribution rights to a compound for a condition associated with chemotherapy | $24.3 | 3DP will make an up-front payment of 500,000 shares, worth about $4.2M; it also will make milestone payments valued at about $20.1M (1/8) |
| 3-Dimensional Pharmaceu- | Johnson & Johnson Pharmaceutical Research & Development | Alliance to discover and optimize small-molecule leads directed at genomics targets | ND | 3DP will receive an up-front technology access fee for its DiscoverWorks technology and research funding during the research collaboration; 3DP also will receive milestone payments and royalties (1/4) |
| Accelrys Inc. | AstraZeneca | Licensing agreement to use Accelrys' simulation software for life science research | ND | Researchers can access any of Accelrys' current libraries of modeling and simulation software for pharmaceutical discovery and development applications (1/28) |
| Albany | Pfizer Inc. | Three-year agreement in which AMRI will provide chemistry research, development and analytical services in a number of therapeutic areas | ND | The contract includes fee-for-service provisions as well as opportunities for AMRI to receive success fees for early or cost-saving completion of projects (12/17) |
| Applied | Eli Lilly & Co. | Collaboration to optimize two of Lilly's protein therapeutics | ND | Deal includes an up-front signing fee, milestone payments and royalties on sales; Lilly retains the right to develop and commercialize products (12/19) |
| Archemix | Noxxon Pharma | Agreement for a worldwide exclusive sublicense to a portion of Archemix's aptamer technology portfolio | $5 | Noxxon will use the technology to develop oligonucleotide therapeutics (1/3) |
| Argenta | GlaxoSmith- | Research agreement to undertake a medicinal chemistry lead optimization program | ND | Argenta will supply focused libraries and single compounds to GSK's drug discovery center based at the Stevenage Medicines Research Center in the UK (12/17) |
| Argenta | H. Lundbeck | Collaboration involving lead compounds within one of Lundbeck's central nervous system programs | ND | The agreement involves potential downstream revenues and payments (1/28) |
| Array Bio- | Pfizer Inc. | Nonexclusive agreements to provide Pfizer with chemical compounds from the Array Discovery Platform | ND | Pfizer will use the compounds for its internal drug discovery program (1/15) |
| Athersys | Pfizer Inc. | Multiyear drug discovery collaboration to provide cell lines expressing protein drug targets for undisclosed indications | ND | Athersys will receive licensing fees for each validated target cell line it delivers, milestone payments and royalty payments (12/13) |
| Atrix Labora- | Sanofi- | Exercised option for the right to develop a dosage form of Leuprogel | ND | Sanofi exercised the option; Atrix will receive research and development funding, as well as payments for certain regulatory and sales milestones, plus a royalty based on sales (1/3) |
| Atugen AG | Byk Gulden | Evaluation agreement of the GeneBloc technology | ND | Companies will investigate the efficiency and specificity of Atugen's Gene-Bloc technology for the validation of novel cancer targets (11/28**) |
| Atugen AG | Novo Nordisk | Agreement to validate novel genetic targets associated with diabetes and related diseases | ND | Atugen will develop GeneBlocs that inhibit expression of specific genetic targets selected by Novo Nordisk; Atugen will receive up-front and annual payments, as well as potential future milestones and royalties (1/9) |
| Avanir Pharma- | Shanghai New | Research and development agreement to market Avanir's docosanol 10% cream in China for the treatment of cold sores and other topical viral indications | ND | Shanghai will conduct and finance product development necessary for regulatory approvals for all indications (1/16) |
| Axxam S.r.l. | Bayer AG | Collaboration in the field of post-genomics to develop several technology platforms for drug discovery | EUR30 | Bayer will obtain a minority stake in Axxam; both companies signed a parallel five-year research deal valued at EUR30M (US$26.5M), which involves Axxam developing a new generation of advanced assay systems to be used at Bayer's ultra-high-throughput screening unit for drug discovery (11/18) |
| BioFocus plc | GlaxoSmith- | Research agreement for the development of new drug leads to treat asthma and chronic obstructive pulmonary disease | ND | GSK will provide BioFocus with details of hit molecules identified from a screening program; BioFocus will optimize the molecules (12/18) |
| BioFocus plc | UCB Pharma | Collaboration on a technology program for the discovery of new drugs active at G protein-coupled receptors | ND | UCB will pay BioFocus a technology access fee and pay for ongoing design, synthesis and lead optimization; the agreement includes milestone payments (2/13) |
| Biophage | Biopolymer | Agreement to research and commercialize pharmaceutical applications of immune modulators against a variety of biological agents, including anthrax, smallpox, plague and brucellosis | ND | The goal is to develop an alternative or adjunctive approach to antibiotics or vaccines through the enhancement of the innate immune defense system against infections (2/1) |
| Biora AB | Molnlycke | Agreement for worldwide rights, excluding Japan, to Biora's development project in wound healing for chronic skin ulcers | SEK10 | Biora will receive a lump sum of US$953,781, as well as the right to milestone payments and royalty payments (12/6) |
| Celera | Otsuka Pharma- | Multiyear subscription agreement for the Celera Discovery System | ND | Agreement is for Otsuka to use Celera's database products, bioinformatics systems and other discovery tools in its research (11/19) |
| Celera | Serono SA | Agreement for a multi-year subscription to Celera's genomic databases | ND | The mouse and human genome sequences will support Serono's drug discovery program (12/20) |
| CeNeS Pharm- | Scion Pharma- | Agreement for Scion to acquire CeNeS' chemical libraries and associated intellectual property rights in the areas of sodium and calcium ion channels, as well as glutamate and sigma receptors | $2.8 | Scion will pay CeNeS $800,000 in staged payments and up to $2M in milestone payments (11/29) |
| CeNeS Pharm- | Wyeth-Ayerst | Agreement granting Wyeth the use of CeNeS' proprietary automated ion channel drug discovery technology | ND | The system allows genuine electro-physical screening of ion channels at high throughput, potentially increasing the rate of the drug discovery process in ion channels (11/28**) |
| Cephalon | Sanofi- | Agreement to co-develop and co-market angiogenesis inhibitors for oncology in a deal worth up to $32M for Cephalon for the first product | $32 | The companies will jointly develop and market the inhibitors in the U.S., Canada and Mexico; the agreement focuses on CEP-7055; the deal includes an up-front license fee, milestone payments and royalties (12/20) |
| ChemBridge | Pfizer Inc. | Discovery chemistry collaboration to design, develop and produce combinatorial compound libraries for Pfizer's compound file | ND | Pfizer will make an equity investment in CRL in addition to annual research and development funding for both ChemBridge and CRL (1/22) |
| Chemical | Novo | Agreement giving Novo access to CDL's lead-like biased combinatorial compounds libraries | ND | CDL will supply Novo with selected compounds crafted in-house based on specific sets of CDL and Novo building blocks (1/24) |
| Chem- | DuPont Crop | Two-year agreement to use ChemNavigator's web-based cheminformatics technology and chemistry procurement service | ND | DuPont scientists will use ChemNavigator's iResearch System to design compound libraries relevant to a particular area of research (2/1) |
| Chiron Corp. | Bristol-Myers | Agreement for a nonexclusive license for the research, development and commercialization of small-molecule therapeutics | ND | The therapeutics will be targeted against a broad spectrum of hepatitis C virus drug targets contained in the HCV genome (11/27) |
| CIMA Labs | Unnamed | Development, license and supply agreement for seven new undisclosed prescription products based upon CIMA's DuraSolv fast-dissolve drug delivery system | $15 | The agreement is expected to result in product development fees between $12M and $15M over the next three years; CIMA will be the exclusive manufacturer of these products and will receive royalties based on sales (12/19) |
| Corixa Corp. | Beaufour Ipsen Group (France) | Exclusive worldwide agreement to develop and market AnergiX.MG technology for the treatment of myasthenia gravis | ND | Beaufour will pay Corixa an up-front license fee, research support, milestone payments and royalties (1/15) |
| DeCode | Pharmacia | Alliance to identify the role of genetics in the development of advanced forms of heart disease | ND | DeCode will employ its population resources and Clinical Genome Miner discovery system to find genetic markers (1/15) |
| DeCode | Roche | Three-year alliance to discover and develop therapeutics based on the achievements of a previous gene discovery collaboration | ND | The deal is an outgrowth of a $200M agreement from 1998 calling for DeCode to research genes or alleles with mutations that predispose people to 12 diseases; in the new agreement, the companies will develop therapeutics for four of the 12 diseases; Roche will provide two years of research funding (1/29) |
| Demegen | DFB Pharma- | Letter of intent granting DFB an exclusive period for evaluation of Demegen's D2A21 and an option to obtain an exclusive license worldwide | ND | If DFB approves of the evaluation's results, the companies expect to enter an exclusive worldwide license for topical dermatological applications (2/7) |
| DGI Biotech- | Novo Nordisk | Two-year licensing and research agreement for the research and discovery of insulin-like growth factor-related antagonists for the treatment of cancer | ND | Novo obtains exclusive rights to IGF antagonists, while DGI maintains rights to IGF agonists discovered through the collaboration (1/8) |
| Discovery | Pfizer Inc. | Agreement to develop and produce libraries of high-purity chemical compounds to be used in Pfizer's drug discovery programs | $95 | The potential value of the four-year collaboration is $95M (12/20) |
| Diversa Corp. | BASF | Collaboration to evaluate selected biocatalysts and biological processes | ND | Any commercialized products will generate license revenues and royalties for Diversa (12/21) |
| Entelos Inc.* | Pfizer Inc. | Science and technology collaboration in which Entelos will prioritize specific Pfizer asthma drug candidates based on their predicted clinical efficacy using Entelos' Asthma PhysioLab technology | ND | Pfizer will provide research funding and license fees to Entelos, as well as success fees and milestone payments (12/12) |
| Evotec OAI | Merck & Co. | Agreement to synthesize small-molecule chemical libraries | ND | Evotec will synthesize drug-like library compounds using its combinatorial chemistry and autopurification platforms; Merck will use the compounds in its drug research and development programs (12/3) |
| Exelixis Inc. | Schering- | Collaboration to create a customized high-throughput screening compound collection to enhance its drug discovery programs | ND | The collaboration will focus on further enhancing the diversity and density of compound collections of both companies and the compounds will be available to each company for internal research programs (1/7) |
| ExonHit | BioMerieux | Five-year alliance to develop ExonHit's cancer diagnostic, Proof-Hit, for breast and colon cancer | ND | ExonHit will leverage its core Datas technology to define genetic signatures that will be compiled on its analytical macroarrays (12/5) |
| Flamel Tech- | Laboratoires | Licensing agreement for the Micropump control-release technology | $42 | Servier will give Flamel a $3M up-front payment; Flamel said the deal is worth at least as much as the company's deal with Novo Nordisk A/S would have been worth, or $42M; the Novo deal was terminated (1/11) |
| Fluidigm | GlaxoSmith- | Agreement for Fluidigm's microfluidic platform technology | ND | Fluidigm will provide GSK with novel microfluidic tools and design software, as well as customized prototype microfluidic chips; GSK will use Fluidigm multi-layer soft lithography technology to explore microfluidic applications (2/11) |
| Galapagos | Pharmacia | Collaboration for the identification and validation of drug targets and therapeutic genes | ND | Galapagos will use its PhenoSelect expression platform to construct a gene library for Pharmacia for the identification and validation of novel drug targets in a broad range of disease areas (11/28) |
| Genaissance | AstraZeneca | Agreement under which the companies will apply Genaissance's gene variation technology to one of AstraZeneca's target discovery programs | ND | AstraZeneca will gain access to specific haplotypes and also use the DecoGen Informatics platform for correlating HAP markers to disease and/or clinical outcomes (12/11) |
| Gene Logic | Aventis Pharma- | Genomics database agreement in which Aventis will establish a CustomSuite | ND | The subscription will give Aventis access to a customized selection of biosamples from Gene Logic's GeneExpress Suite (12/13) |
| Gene Logic | GlaxoSmith- | Agreement in which GlaxoSmithKline adopted Gene Logic's GeneExpress suite of information products | ND | GlaxoSmithKline will use the products, including the BioExpress module, in its drug discovery and development efforts (12/10) |
| Gene- | Bristol-Myers | Collaboration to jointly advance the development of nuclear magnetic resonance software for the automated, high-throughput determination of 3-D protein structures derived from NMR data | ND | Financial details were not disclosed (1/7) |
| GeneProt | Waters Corp. | Partnership to expand GeneProt's proteomics capabilities through its new industrial-scale proteomics facility in the U.S. | $10 | Waters, through its subsidiary, Micromass UK Ltd., will purchase equity securities of GeneProt with a maximum value of $10M; GeneProt will purchase about $20M of mass spectrometry equipment, related systems and services from Micromass (12/3) |
| Genfit SA | BioMerieux- | Three-year research collaboration with BioMerieux for the identification of the molecular mechanisms of action of new drug candidates for the treatment of cardiovascular diseases; and a deal with Fournier for five years calling for the identification of new therapeutic targets in the field of metabolic diseases | US$8.8 | The two deals provide Genfit with guaranteed research and development funding of at least US$8.8M over five years; Genfit also is entitled to possible milestones and royalties (11/28) |
| Genomics | Wyeth-Ayerst | Agreement enabling Wyeth to use the GCI Access program for genomics-based target discovery and validation | ND | GCI Access gives Wyeth researchers defined access to the Global Repository (1/8) |
| Genzyme | Kirin Brewery | Multimillion-dollar collaboration to develop and commercialize fully human monoclonal antibodies as therapies in anti-angiogenesis and vascular targeted cancer drug delivery | $2 | Terms include a $2M up-front fee for Genzyme plus two years of full research funding; Genzyme also will receive milestone payments (11/19) |
| GPC Biotech | Altana AG | Agreements related to the establishment of a genomics research center in Waltham, Mass. | $120 | GPC will provide Altana with licenses, capacities for collaboration and facilities related to the new research center, in return for up to $70M of a potential $120M investment (11/8) |
| Guilford Pharm- | MAP Medical | Guilford licensed European development and commercialization rights for Dopascan injection to MAP | ND | Guilford will receive an initial up-front payment, milestone payments and royalties on future product sales (1/2) |
| Immuno- | Sanofi- | Co-development agreement covering the whole range of IDM's "cell drugs" for cancer | EUR | The deal could be worth as much as US$545M to IDM if Sanofi-Synthelabo develops and commercializes the maximum number of products covered in the deal (1/22); Sanofi exercised its first option to develop and market IDM's cell drug, IDD3, for melanoma (2/19) |
| ImmunoGen | Boehringer | Agreement to develop a less toxic cancer therapeutic using ImmunoGen's Tumor-Activated Prodrug technology | ND | Boehringer Ingelheim gains exclusive worldwide rights to commercialize resulting products; it also gains responsibility for manufacturing preclinical and initial clinical materials for manufacturing payments (11/28) |
| Inex Pharma- | GlaxoSmith- | Licensing agreement for Inex's drug delivery technology, TransMembrane Carrier System | $36 | GlaxoSmithKline will use the technology to make targeted cancer drugs; the products will be developed using GSK's camptothecin compound topotecan hydrochloride, currently marketed as Hycamtin; GSK will pay $36M up front and milestone fees; Inex also will receive royalties on product sales; GSK is responsible for all development costs (11/20) |
| Infectech Inc. | ERBC | Testing and licensing agreement for the Infectech technology for early identification of tuberculosis and M. avium bacteria and the Infectech technology developed for bioterrorism defense | ND | ERBC also has the right to acquire a license to sell Infectech technology in Europe, Russia and the Middle East for a minimum of 20 years through the purchase of $1M in Infectech common stock (1/24) |
| Interleukin | Kaiser Perma- nente's Center | Research collaboration to study genetic risk factors for chronic diseases that are affected by inflammation | ND | Financial details were not disclosed (12/19) |
| ISTA Pharma- | Otsuka Pharm- | Agreements for Vitrase for the treatment of severe vitreous hemorrhage and diabetic retinopathy | $4 | Otsuka gained exclusive rights for the development and commercialization of Vitrase in Japan; ISTA will manufacture the product; Otsuka made an initial license fee payment and will make an additional payment when Vitrase is approved in Japan; Otsuka made a $4M equity investment in ISTA (12/20) |
| Keryx Bio- | Yissum | Exclusive worldwide licensing agreement to a novel technology known as small, integrated building blocks, for the conversion of peptides and other existing drugs into small molecules that have the potential for oral delivery | ND | The technology uses modular building blocks in order to mimic a targeted peptide or rigid small molecule (1/16) |
| LifeSpan | Procter & | Subscription agreement for the GPCR Localization Database | ND | P&G gains access to LifeSpan's database; financial terms were not disclosed (2/12) |
| Menarini | Tanabe | Agreement to collaborate on worldwide development of T-0128 | ND | T-0128 is an anticancer agent in the early development stage in Japan (2/4) |
| Mologen AG | Schering AG | Contract agreement to develop cell-based therapies, including treatments of cancer, with Mologen's MIDGE technology | ND | A third party in the project is SynerGene Therapeutics Inc., which also develops solutions for targeted delivery of therapeutics (1/28) |
| Morphochem | Aventis | Collaboration to discover and develop small molecules for a range of bacterial infections | $30 | Morphochem will generate small-molecule compounds with anti-infective capability against a novel target; Aventis Pharma will provide funding for Morphochem, as well as complementary research and preclinical development; Morphochem may receive up to $30M in research and development and milestone payments (1/24) |
| MorphoSys | Schering AG | Collaboration for the development of antibody therapeutics and in vivo diagnostics | ND | Schering will purchase a 10% equity stake in MorphoSys and MorphoSys will receive committed license fees and research and development funding over the three-year collaboration; the companies expect to pursue a minimum of five therapeutics and several in vivo diagnostics projects (12/20) |
| MultiCell | Pfizer Inc. | Collaborative research agreement involving the validation of MultiCell's Immortalized liver cells | ND | The validation will be used to predict, among other things, the toxicological and therapeutic properties of drug candidates (11/15) |
| Myogen | Abbott | Agreement for exclusive worldwide rights to develop and take to market the endothelin receptor antagonist BSF 208075 | ND | Myogen will provide up-front money and milestone payments, as well as royalties (11/29) |
| Nastech Pharm- | Pharmacia | Licensing agreement for nasally administered apomorphine product for sexual dysfunction in both men and women | $56.4 | Pharmacia will be responsible for all further development; it gains exclusiveworldwide marketing rights; the deal includes a $3M up-front payment, $45M in milestone payments, and Pharmacia will purchase 250,000 shares of Nastech common stock for $5M; it also includes royalties (2/4) |
| NeoGenesis | Aventis Pharma | Agreement for NeoGenesis to use its chemical genomics technologies to identify therapeutic agents for infectious diseases in a multiyear collaboration | ND | The deal will provide NeoGenesis with an up-front payment, a multiyear commitment of research and development funding, preclinical and clinical milestones and royalties (2/14) |
| Neose | Wyeth-Ayerst | Research, development and license agreement for the use of Neose's Glyco-Advance technology to develop an improved production system for Wyeth's product, P-selectin glycoprotein ligand | $17 | Neose will develop processes for the commercial-scale manufacture of enzymes and sugar nucleotides used to produce rPSGL-lg (12/21) |
| NeoThera- | Pfizer Inc. | Agreement relating to the use of an orphan receptor identified by NeoGene, a NeoTherapeutics' subsidiary | ND | NeoTherapeutics will receive an initial payment and milestone payments (12/20) |
| Neurogen | Aventis Pharma | Agreement to develop stress-related drugs | $10 | Neurogen receives a $10M initial payment, milestone payments and royalties; Aventis gains exclusive worldwide development, manufacturing, marketing and sales rights to compounds that come out of the collaboration (12/20) |
| NeuroSearch | Boehringer | Agreement to develop and market a drug for the treatment of Alzheimer's and Parkinson's diseases | $80 | The deal includes $20M in an up-front payment and $60M in milestone payments prior to marketing; the deal focuses on a compound called NS2330 (2/8) |
| Orchid Bio- | Beckman | Nonexclusive license to use Orchid's SNP-IT primer extension technology to develop SNP scoring products for the research market on multiple platforms | ND | Beckman Coulter can produce and sell reagent kits, software and systems globally; Orchid will receive an up-front payment and may see royalties on consumable product sales (1/31) |
| Oxford | Pfizer Inc. | Research agreement in which OGS will continue to apply its industrial-scale proteomics technology | ND | The technology will be used in the discovery and utility of biomarkers in atherosclerosis, Alzheimer's disease and certain other undisclosed targets and indications (12/14) |
| Pharmacopeia | NV Organon | Five-year agreement to discover lead compounds | ND | Organon will provide a number of assays using about 20 to 30 of its biological targets; Pharmacopeia will apply its sample collection of small molecules and high-throughput and ultra-high-throughput screening capabilities to discover lead compounds (2/13) |
| Phylos Inc.* | Aventis | Agreement giving Phylos a division of AR&T and creating a wholly owned subsidiary, Phylos GmbH | ND | Phylos reacquired all rights to the PRO-fusion technology and recovered the right to grant sublicenses to third parties (1/8) |
| ProBioGen AG | Merck & Co. | Exclusive research and license agreement to explore the development of cell substrates with potential application in the production of biologicals | ND | ProBioGen will receive an up-front payment and potential milestone payments, as well as royalties (12/7) |
| Proneuron | Teva Pharma- | Agreement to expand development of Copaxone | $10 | Teva gains rights to develop the product for neurological diseases, such as Alzheimer's, stroke, brain trauma, glaucoma and Parkinson's; Proneuron will receive payments related to clinical and regulatory milestones, as well as royalties; Teva also made a $10M equity investment in Proneuron; Teva will fund all development and commercialization of the indications it pursues, and will pay for certain preclinical research activities at Proneuron (12/4) |
| Sangamo | Wyeth-Ayerst | Collaborative research agreement in which Sangamo will provide gene-specific, zinc-finger DNA-binding proteins to Wyeth-Ayerst | ND | Wyeth-Ayerst will use the proteins in its internal research programs (1/16) |
| Silicon | AstraZeneca | Licensing agreement for Silicon's enterprise-wide products | ND | The license is for GeneSpring, GeNet and Script Editor, designed for a genomics discovery platform (1/15) |
| Specialty | Beckman | Cross-licensing agreement for the development of multi-analyte assays on Beckman Coulter's new Progressive MicroArray platforms | ND | Specialty Laboratories also will have early access to Beckman Coulter's Universal Linker capture technology (2/13) |
| Structural | Boehringer | Research collaboration to use SBI's Variome database for Boehringer's in silico drug discovery of HIV protein targets | ND | Financial terms were not disclosed (12/17) |
| Structural | Aventis Pharma- | Agreement in which Structural GenomiX will identify lead compounds by solving the structures of up to 100 compounds for a designated drug target set for Aventis | ND | Aventis will provide high-throughput screened compounds selected against the human drug target, and SGX will co-crystallize the compounds against the target; the deal includes an up-front payment and milestone payments for SGX (1/7) |
| Symyx Tech- | Eli Lilly & Co. | Agreement to enhance the rapid discovery, identification and characterization of novel polymorphic forms of Lilly's drug candidates | ND | Lilly will purchase a Symyx polymorph Discovery Tools system and two Symyx solubility workflow systems (1/7) |
| Synt:em | Baxter | Research agreement to develop mimetics of the binding regions of selected proprietary monoclonal antibodies | ND | Synt:em will use its Para:mim technology to design the mimetics, which consists of small peptides exhibiting binding and activity similar to that of Baxter's monoclonal antibodies (1/28) |
| Syrrx Inc.* | Pharmacia | Multiyear research collaboration to use Syrrx's high-throughput, automated structural proteomics technology platform to determine 3-dimensional shapes of proteins, which will become targets of drugs to treat cancer, inflammation and infectious diseases | ND | Financial terms include a technology access fee, a potential equity investment in Syrrx, R&D funding and success payments (1/24) |
| Theratech- | Sakai Chemical | Licensing agreement for the development and marketing in Japan of ThGRF peptide, or TH 9507 | US$36 | The initial indication will be for hip fractures; Theratechnologies also gives Sakai the option to develop the growth hormone-releasing factor analogue in chronic obstructive pulmonary disease, sleep disorders and immune dysfunction (2/5) |
| TransTech | Novo Nordisk | Three-year research collaboration to focus on the discovery and development of new targets in diabetes | ND | The agreement involves a TransTech program in diabetes that Novo Nordisk is supporting in return for exclusive worldwide rights to certain products; Transtech will receive an up-front payment, three years of research support and potential milestones and royalties (11/30) |
| Tripos Inc. | Pfizer Inc. | Three-year, multimillion-dollar collaboration to develop and deploy Lithium | ND | Lithium is a new software platform designed to enhance the speed and efficiency of drug discovery (1/4) |
| Tripos Inc. | Pfizer Inc. | Four-year chemistry collaboration in which Tripos will design, synthesize and purify compounds to build the Pfizer library | $100 | The number of compounds was not disclosed (1/7) |
| UroGene | Pierre Fabre | Three-year research collaboration to discover and develop new active compounds to treat prostate cancer against a validated biological target identified by UroGene | EUR10 | UroGene will receive an up-front payment, milestones and other research and development income totaling up to US$9M; it also will receive royalties on product sales (1/30**) |
| Vernalis | F. Hoffmann- | Agreement to collaborate on the research and development of drugs to treat diabetes | ND | Roche will have exclusive worldwide marketing rights and will be responsible for all development and regulatory activities; Vernalis will receive research funding, milestone payments and royalties (2/13) |
| Vernalis | Roche | Research and development agreement that focuses on anti-obesity drugs | ND | The collaboration aims to develop highly selective 5-HT(2C) receptor agonists as appetite suppressants; Roche has rights to product candidates and will pay royalties to Vernalis on worldwide net sales; terms include research funding and milestones payable to Vernalis (2/11) |
| Vical Inc. | Aventis | Agreement giving Aventis rights to use Vical's gene delivery technologies for specific oncology applications | ND | Aventis Pasteur is paying an undisclosed licensing fee and giving up its rights to develop and commercialize infectious disease vaccines and gene-based therapeutics for neurodegenerative diseases that were previously licensed from Vical (12/14) |
| Xenerex | DNAX | Agreement to generate fully human monoclonal antibodies to a pair of target antigens provided by DNAX, which will evaluate them for possible development as drugs | ND | Xenerex gets research fees for the use of its technology, and could get more if DNAX enters a commercial license deal (1/23) |
| | ||||
Notes: |
||||
| # The information in the chart does not cover agricultural agreements or those between biotech companies. |
||||
| * Private companies are indicated with an asterisk; unless otherwise noted, stock symbols listed are on the Nasdaq market. |
||||
| ** Denotes the date the item ran in BioWorld International. |
||||
| ND = Not disclosed, reported and/or available |
||||
| AMEX = American Stock Exchange; BSX = Berlin Stock Exchange; FSE = Frankfurt Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over the Counter Bulletin Board; SSE = Stockholm Stock Exchange; TSE = Toronto Stock Exchange |
||||
